Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 4254
Extension of Research License Period. With respect to each Research Antigen, Licensee shall have the option to extend the term of the Research License Period for one additional 6 month period by providing written notice and paying an extension fee.
Option for Exclusive Commercial Licenses. Subject to the availability of particular Antibodies to a Research Antigen for exclusive licensing by Licensee, during the term of the applicable Research License Period, Licensee shall have a non-exclusive option to obtain an Exclusive Commercial License. The option shall terminate at the end of the Research License Period for the applicable Research Antigen.
Exclusive Commercial License. If Licensee elects to exercise its option to acquire an Exclusive Commercial License, Licensor grants on an Antibody-by-Antibody basis, a worldwide, exclusive, non-transferable, royalty-bearing license under the Licensor Technology and Licensor's rights in the Mice, with the rights to sublicense, to use, or, pursuant to a Manufacturing Services Agreement, have Licensor use, the Mice to develop, make, have made, import, have imported, use, offer for sale and sell Products containing such Licensed Antibody, which license is non-exclusive with respect to a Research Antigen and exclusive with respect to the specific Antibody.
Sublicenses. Licensee may grant sublicenses under and Exclusive Commercial Licenses to the extent necessary for Sublicensees to develop, make, have made, import, use, offer for sale and see Products; provided , however, that within 10 days following the date any such sublicense is executed, Licensee shall notify Licensor.
1. Human Transcobalamin II (TCII) – in recombinant form.
2. Human Transcobalamin II/Vitamin B12 (coballamin) receptor in semi-purified membrane preparation form extracted from human placenta.
IPSCIO Record ID: 222549
For the commercial license, Licensor grant the following licenses, on an Licensee Target-by-Licensee Target basis
– a worldwide, exclusive, non-transferable license, with the right to grant a sublicense to its Affiliates, under the Licensor Technology to immunize the Mice to make Antibodies against such Licensee Target, and
– a worldwide exclusive license under the Licensor Technology, with the right to sublicense, to make, have made, import, have imported, use, offer for sale and sell Products containing Antibodies against such Licensor Target.
Licensee shall have no right to grant sublicenses to use the Mice, but may grant sublicenses under
the Licensee Technology to the extent necessary to develop, make, have made, import, use, offer for
sale and sell Products.
Licensor Technology includes the Confidential Information and Mice, and patent rights which claims an invention which is necessary for the use of the Mice to prepare the Antibodies or to develop, produce, make, have made, import, have imported, use, offer for sale and sell the Antibodies.
The Product shall mean any composition or formulation comprising one or more Antibodies, or a portion thereof, for the diagnosis, prophylaxis or treatment of human disease.
Licensee Target shall mean an Antigen selected by Licensee for immunization of Licensors HuMAb mice to generate human antibodies directed against an Antigen, in each case, which Licensor has informed Licensee is available for licensing.
HuMAb -Mouse technology is a transgenic mouse system that creates high affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.
Incorporating this technology into Licensee's broad drug discovery program will significantly enhance Licensee continuing efforts to identify new drug candidates.
IPSCIO Record ID: 109479
(a) an exclusive, worldwide, non-transferable license under the Licensors Technology to use the Mice to make Antibodies, and
(b) an exclusive, worldwide license under the Licensors Technology, with the right to sublicense, to use such Antibodies to make, have made, import, have imported, use, offer for sale and sell Products.
Antibody means a human monoclonal antibody with binding affinity for an Antigen derived by Licensee or its Affiliates or Sublicensees from cells obtained from one or more of the Mice.
Product shall mean any product for the treatment of human disease containing an Antibody with affinity for CRI, or a bispecific antibody consisting of a combination of an Antibody with affinity for CRI and an Antibody to Staphylococcus aureus.
'Mice' shall mean immunizable sterile transgenic mice containing unrearranged human immunoglobulin genes.
IPSCIO Record ID: 942
Product shall mean any product for the treatment or diagnosis of human disease containing an Antibody provided by Licensor or produced from any hybridoma provided by Licensor or a portion thereof.